Clinical Trial Update: An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan. [Phase 3]

View source ↗

Summary

A Phase 3 open-label extension study evaluating safety and tolerability of LCZ696 (sacubitril/valsartan) in Japanese patients who completed PARAGON-HF; terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 3 | Status: TERMINATED | Results posted: 2020-12-04